Study of CTX112 for adults with autoimmune disease
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests an experimental cell therapy called CTX112 for people with lupus, scleroderma, or inflammatory myositis that hasn't responded well to standard treatments. The goal is to see if it's safe and if it can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 69 years old.
- You have been diagnosed with lupus, scleroderma, or inflammatory myositis by a specialist.
- Your heart, lungs, kidneys, liver, and blood counts are working well enough.
- You have not had a previous treatment targeting CD19 or any gene/cell therapy before.
- You do not have an active serious infection or cancer in the last 5 years (except low-risk cancers).
- You are not pregnant or breastfeeding and agree to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational cell therapy called NKX019 for people with certain autoimmune diseases like scleroderma, myositis, vasculitis, or rheumatoid arthritis. It aims to see if NKX019 can help control the disease when standard treatments have not worked well enough.
This trial is testing an investigational medicine called PF-08154225 for people with autoimmune diseases like rheumatoid arthritis, lupus, myositis, or systemic sclerosis. It aims to see if the drug is safe and effective in reducing disease activity.
This trial tests a new cell therapy called YTS109 for people with several autoimmune diseases that have not improved with standard medications. It aims to see if this treatment can help control the disease when other treatments have failed.
This trial tests an investigational drug called AZD0120 in adults with lupus that hasn't improved with standard treatments. The goal is to see if it's safe and works well for people with lupus-related organ problems.
This Phase 1/2 study tests how safe and effective CTX112 is for adults whose B-cell cancer has returned or is not responding to treatment. It aims to see whether CTX112 can control the cancer while monitoring side effects closely.
This study tests a new treatment called CC312 for people with lupus, myositis, or scleroderma that hasn't gotten better with standard therapies. It aims to see if CC312 can help control the disease when other treatments have failed.
Hear when a new SLE (Systemic Lupus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.